

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(c) EXHIBITS

Exhibit 99.1 Press Release dated August 5, 2003

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 5, 2003 the Company reported its results for the three and six months ended June 30, 2003. The earnings release is attached as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Selas Corporation of America

By: /s/ Robert F. Gallagher

Robert F. Gallagher
Vice President and Chief Financial Officer

Date: August 5, 2003

Exhibit 99.1

FROM: SELAS CORPORATION OF AMERICA

SCA-444

CONTACT: Robert F. Gallagher 651-604-9638

FOR IMMEDIATE RELEASE

SELAS CORPORATION OF AMERICA REPORTS

SECOND-QUARTER RESULTS; FRENCH SUBSIDIARY FILES INSOLVENCY

Precision Miniature Medical and Electronic Products Business
Grows from Year-Ago Period

ST. PAUL, Minn. - August 5, 2003 - Selas Corporation of America (AMEX: SLS) today reported results for the second quarter and six months ended June 30, 2003.

For the second quarter, the Company had a net loss from continuing operations of \$649,000, or \$.13 per share, on sales of \$17.2 million. This compares with continuing operations net income of \$74,000, or \$.01 per share, on sales of \$18.0 million for the second quarter of 2002. For the six-month period, the Company reported a net loss from continuing operations of \$1,078,000, or \$.21 per share, on sales of \$31.9 million, versus net income of \$93,000, or \$.02 per share, on sales of \$34.7 million for the year-ago six months.

Selas recognized a net loss of \$682,000, or \$.13 per share, from discontinued operations for the second quarter, compared with net income from discontinued operations in the comparable year-earlier period of \$157,000, or \$.03 per share. Second-quarter 2002 discontinued operations include: Selas' large furnace operation, which was sold in December 2002, and Deuer

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

Manufacturing, which was sold in July 2003.

For the second quarter of 2003, Selas reported a total net loss of \$1,331,000, or \$.26 per share, compared with net income of \$231,000, or \$.04 per share, in 2002. For the six months ended June 30, 2003, the total net loss was \$1,567,000, or \$.31 per share, compared with a net loss of \$10,459,000, or \$2.04 per share, for the year-ago period. 2002 six-month results included a \$10.6 million, or \$2.06 per share loss, due to a goodwill change in accounting.

Mark S. Gorder, president and chief executive officer of Selas, reiterated that the Company's long-term strategy is to create accelerated growth for its Precision Miniature Medical and Electronic Products business. Selas' core competencies position it well to expand its line of medical products to capture significantly more business. 'With our expertise in the robotic manufacture of miniature and micro-miniature electronic products, we believe we are well-suited to compete in a medical device market,' Gorder said.

For the six months ended June 30, 2003, Precision Miniature Medical and Electronic Products sales increased 6 percent to \$18.7 million, from \$17.5 million in the comparable 2002 period. Net income rose to \$626,000 from \$432,000 in the prior year. Results for this business were buoyed by Selas' small, but growing medical component business that saw year-over-year revenue growth of 98 percent. The medical component increase was primarily due to components within third-party medical products to detect air bubbles in IV lines and for safety needles included as part of implanted drug delivery systems. However, income from this segment was more than offset by losses in the company's Heat Technology segment and by corporate expenses.

Selas SAS

After four consecutive quarters of substantial losses together with a \$1.3 million adverse judgment in the French Courts related to a subcontractor lawsuit, Selas' wholly owned French subsidiary, Selas SAS, filed for insolvency yesterday. Under French law, Selas SAS will be put in the hands of a government court administrator.

Gorder stated: "Our Heat Technology business in Europe has suffered from the weak global capital-goods markets and the strengthening of the Euro. Deterioration of the business over the past four quarters and an uncertain future required Selas SAS to take this action."

As a result of the filing, Selas Corporation of America will take a minimum pre-tax charge of \$1.6 million in the third quarter. In addition, the Company may incur additional liabilities related to corporate guarantees and joint obligations or possible legal action against Selas in French courts; however, the Company cannot predict the impact of any such liabilities or actions on Selas.

"We regret Selas SAS filing for insolvency; however, we believe without substantial additional investment, Selas SAS would be difficult to turn around. We believe this action is in the best long-term interest of Selas Corporation of America and its shareholders," Gorder said.

As a result of the losses incurred to date and the insolvency of Selas SAS, the Company is out of compliance with certain covenants with its bank lenders. Management is currently in discussions with its banks to obtain the appropriate waivers.

Gorder concluded, "Strong second-quarter performance for our Precision Miniature Medical and Electronic Products shows that we're on track for the future. We're building the company around these core product lines and divesting ourselves of our non-core assets."

About Selas

Headquartered in St. Paul, Minn., Selas Corporation of America designs, develops, engineers and manufactures microminiaturized medical and electronic products. The company's core business segment, Precision Miniature Medical and Electronic Products, supplies microminiaturized components, systems and molded plastic parts, primarily to the hearing instrument manufacturing

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

industry, as well as the computer, electronics, telecommunications and medical equipment industries. Through its core competencies and robotic manufacturing expertise, Selas is well-positioned to compete in the hearing health market and a medical device market that increasingly demands products with increased miniaturization, better cost containment, more reliability and high customer satisfaction. The company has facilities throughout the United States, Asia and Europe. Selas' common stock is traded on the American Stock Exchange under the symbol "SLS."

Forward-Looking Statements

Statements as to the company's long-term strategy and other statements herein that include forward-looking terminology such as "may", "will", "believe", "expect", "optimistic" or "continue" or the negative thereof or other variations thereon are "forward-looking statements" within the meaning of the Securities Exchange Act of 1934 as amended. These forward-looking statements are affected by known and unknown risks, uncertainties and other factors that may cause Selas' actual results, performance or achievements to differ materially from the results, performance and achievements expressed or implied in the company's forward-looking statements. These risks, uncertainties and factors include the risk that the company may not be able to achieve its long-term strategy, risks arising in connection with the insolvency of Selas SAS, competition by competitors with more resources than the company, foreign currency risks arising from the company's foreign operations, the cyclical nature of the market for large custom engineered contracts, weakening demand for products of the company's other business segments due to general economic conditions, and possible non-performance of developing technological products.

Selas Corporation of America Consolidated Statements of Operations

	Three Months Ended	
	June 30, 2003	June 30, 2002
	(Unaudited)	(Unaudited)
Sales, net	\$17,244,911	\$17,983,975
Operating costs and expenses		
cost of sales	13,841,161	14,118,475
Gross margin	3,403,750	3,865,500
Selling, general and administrative expenses	4,129,269	3,891,738
Operating loss	(725,519)	(26,238)
Interest expense	(215,273)	(117,256)
Interest income	6,714	7,902
Other income, net	165,329	159,093
Income (loss) from continuing operations before income taxes	(768,749)	23,501

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

Income tax (benefit)	(119,838)	(50,861)
Income (loss) from continuing operations	(648,911)	74,362
Income (loss) from discontinued operations, net of income taxes (benefit)	(682,268)	156,853
Net income (loss)	\$ (1,331,179)	\$231,215
Income (loss) per share		
Basic		
Continuing operations	\$ (.13)	\$.01
Discontinued operations	(.13)	.03
	\$ (.26)	\$.04
Diluted		
Continuing operations	\$ (.13)	\$.01
Discontinued operations	(.13)	.03
	\$ (.26)	\$.04

Selas Corporation of America
Consolidated Statements of Operations

	Six Months Ended	
	June 30, 2003	June 30, 2002
	----- (Unaudited)	----- (Unaudited)
Sales, net	\$31,880,927	\$34,678,725
Operating costs and expenses		
Cost of sales	24,577,292	27,200,264
Gross margin	7,303,635	7,478,461
Selling, general and administrative expenses	8,349,720	7,575,704
Operating loss	(1,046,085)	(97,243)
Interest expense	(406,184)	(199,894)
Interest income	9,136	23,183
Other income, net	248,915	253,029
Loss from continuing operations before income taxes	(1,194,218)	(20,925)
Income tax (benefit)	(116,463)	(114,266)
Income (loss) from continuing operations	(1,077,755)	93,341
Income (loss) from discontinued operations, net of income taxes (benefit)	(489,686)	(524)

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

Net income (loss) before change in accounting principle	(1,567,441)	92,817
Cumulative effect of change in accounting principle		(10,551,926)
Net loss	\$ (1,567,441)	\$ (10,459,109)
Income (loss) per share		
Basic		
Continuing operations	\$ (.21)	\$.02
Discontinued operations	(.10)	(.00)
Accounting principle change	--	(2.06)
	\$ (.31)	\$ (2.04)
Diluted		
Continuing operations	\$ (.21)	\$.02
Discontinued operations	(.10)	(.00)
Accounting principle change	--	(2.06)
	\$ (.31)	\$ (2.04)

Selas Corporation of America
Consolidated Balance Sheets

	June 30, 2003 (Unaudited)	December 31, 2002 (Audited)
Current assets		
Cash, including cash equivalents of \$415,000 in 2003 and \$418,000 in 2002 and restricted cash of \$415,000 in 2003 and \$418,000 in 2002.	\$ 1,293,127	\$ 2,039,044
Accounts receivable (including unbilled receivables of \$2,404,000 in 2003 and \$1,447,000 in 2002)	16,740,672	15,627,864
Inventories	9,332,828	9,393,802
Refundable income tax	--	336,758
Deferred income taxes	2,160,830	1,818,384
Other current assets	1,767,746	1,064,829
Assets of discontinued operations	12,146,281	13,610,601
Total current assets	43,441,484	43,891,282
Property, plant and equipment		
Land	231,943	231,943
Buildings	5,149,415	5,149,415
Machinery and equipment	32,128,149	29,903,795
	37,509,507	35,285,153

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

Less: Accumulated depreciation	25,324,378	22,921,608
Net property, plant and equipment	12,185,129	12,363,545
Goodwill	5,376,317	5,376,317
Deferred income taxes	373,601	348,712
Other assets, less amortization	1,706,172	1,575,539
	\$63,082,703	\$63,555,395

Liabilities and Shareholders' Equity

	June 30, 2003 (Unaudited)	December 31, 2002 (Audited)
Current liabilities		
Notes payable	\$12,404,543	\$10,920,984
Current maturities of long-term debt	3,246,692	1,573,716
Accounts payable	11,686,286	11,046,373
Customers' advance payments on contracts	2,686,761	2,457,499
Guarantee obligations and estimated costs of service	1,281,242	1,188,361
Other accrued liabilities	8,051,112	6,194,679
Liabilities of discontinued operations	4,982,840	6,955,654
Total current liabilities	44,339,476	40,337,266
Long-term debt	382,406	2,736,236
Other postretirement benefit obligations	4,068,787	3,866,154
Contingencies and commitments		
Shareholders' equity		
Common shares, \$1 par; 10,000,000 shares authorized; 5,634,968 shares issued	5,634,968	5,634,968
Additional paid-in capital	12,008,915	12,012,541
Retained earnings	179,442	1,743,256
Accumulated other comprehensive loss	(2,266,213)	(1,509,948)
Less: 515,754 common shares held in treasury, at cost	(1,265,078)	(1,265,078)
Total shareholders' equity	14,292,034	16,615,739

Edgar Filing: SELAS CORP OF AMERICA - Form 8-K

\$63,082,703 \$63,555,395